Home›Trial›NCT05502341
🔬NCT05502341Phase 2Phase 3ACTIVE NOT RECRUITING

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Study Summary

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).

Conditions
HIV-1-infection
Interventions / Drugs
BictegravirLenacapavirBIC/LEN FDCStable Baseline Regimen
View on ClinicalTrials.gov ↗
Sponsor
GILD
Gilead Sciences
Antiviral
F24/100
Study Details
Enrollment689 participants
Primary Completion—
Lead SponsorGilead Sciences
Data Retrieved2026-04-11 02:55:27.112847+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.